EBS vs ORCL · rev $390.4M vs P/E 31, rev $57.40B
Emergent Biosolutions Inc (EBS) versus Oracle Corporation (ORCL) — a side-by-side from cached financials, not a winner call.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Oracle Corporation (ORCL) is a software - infrastructure company listed on NYSE. It is led by Safra Catz.
Latest reported EBS revenue for 2026-06-30 was $390.4M. Net income was -$173.4M. EBS currently screens at market cap $416.4M.
Latest reported ORCL revenue for 2025-05-31 was $57.40B. Net income was $12.63B. Revenue was up 8.4% from 2024-05-31 to 2025-05-31. ORCL currently screens at market cap $527.84B and trailing P/E 31.4.
EBS currently screens at market cap $416.4M. ORCL currently screens at market cap $527.84B and trailing P/E 31.4.
Not investment advice. Open the EBS and ORCL stock pages for the full models.
Not investment advice.